Lannett Reaches Special Protocol Assessment Agreement With FDA for Cocaine HCl Phase III Trial

Lannett Company announced that it has reached agreement with the FDA on a Special Protocol Assessment (SPA), regarding the design of a Phase III study of the company’s Cocaine HCl topical solution product, C-Topical.
MarketWatch